Modality
ERT
MOA
KRASG12Di
Target
PLK4
Pathway
Complement
Obesity
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
~Jun 2019
→ ~Sep 2020
Phase 3
~Dec 2020
→ ~Mar 2022
NDA/BLA
Jun 2022
→ Sep 2025
NDA/BLACurrent
NCT06715899
2,706 pts·Obesity
2022-06→2025-09·Recruiting
2,706 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-087mo agoPh3 Readout· Obesity
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2025-09-08 · 7mo ago
Obesity
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06715899 | NDA/BLA | Obesity | Recruiting | 2706 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 |